Evoke Pharma, Inc.
EVOK
$5.49
$0.0761.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.06% | 77.48% | 97.40% | 69.83% | 125.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.06% | 77.48% | 97.40% | 69.83% | 125.51% |
| Cost of Revenue | 304.10% | -55.03% | 100.85% | 197.99% | -27.70% |
| Gross Profit | 42.81% | 84.94% | 97.27% | 66.90% | 133.70% |
| SG&A Expenses | 37.54% | 36.88% | 25.88% | 22.12% | 34.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.69% | 35.38% | 26.33% | 24.43% | 29.46% |
| Operating Income | -27.40% | 13.29% | 36.77% | 19.81% | 31.43% |
| Income Before Tax | -23.97% | 17.32% | 39.98% | 22.52% | 32.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.97% | 17.32% | 39.98% | 22.52% | 32.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.97% | 17.32% | 39.98% | 22.52% | 32.16% |
| EBIT | -27.40% | 13.29% | 36.77% | 19.81% | 31.43% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 33.80% | 75.45% | 95.19% | 84.58% | 86.14% |
| Normalized Basic EPS | 33.79% | 75.45% | 95.19% | 84.58% | 86.14% |
| EPS Diluted | 33.80% | 75.45% | 95.19% | 84.58% | 86.14% |
| Normalized Diluted EPS | 33.79% | 75.45% | 95.19% | 84.58% | 86.14% |
| Average Basic Shares Outstanding | 87.25% | 236.77% | 1,147.38% | 402.48% | 389.41% |
| Average Diluted Shares Outstanding | 87.25% | 236.77% | 1,147.38% | 402.48% | 389.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |